Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal

Flora Zagouri, Paraskevi Liakou, Rupert Bartsch, Fedro A. Peccatori, Alexandra Tsigginou, Constantine Dimitrakakis, George C. Zografos, Meletios Athanassios Dimopoulos, H. A. Azim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

An ever growing number of medical organizations, societies, working groups and governmental agencies issue algorithms i.e. guidelines, of decision making flowcharts in diagnosis and treatment in a variety of diseases. In the field of evidence-based diagnosis and treatment of breast cancer, a large number of guidelines are available both from medical associations and national health departments. Among the most appreciated and utilized comprehensive guides is the European Society for Medical Oncology (ESMO) Breast Cancer Guidelines and from the other side of the Atlantic the National Comprehensive Cancer Network (NCCN) Guidelines in Breast Cancer. Although there is much concordance between the guidelines from these two organizations, it is intriguing to locate their discrepancies also. The aim of this report is to present a number of different points between ESMO and NCCN in the whole spectrum of breast cancer management, from prevention and diagnosis to treatment and follow up. This systematic review was performed in accordance with the PRISMA guidelines using a predefined search strategy and summarizes in detail, the differences between ESMO and NCCN guidelines regarding genetic risk evaluation and screening, surgery, chemotherapy, endocrine treatment, targeted biological agents, radiotherapy, pregnancy and fertility and follow-up.

Original languageEnglish
Pages (from-to)513-523
Number of pages11
JournalBreast
Volume24
Issue number4
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Medical Oncology
Guidelines
Breast Neoplasms
Organizations
Software Design
Neoplasms
Medical Societies
Biological Factors
Therapeutics
Fertility
Decision Making
Radiotherapy
Drug Therapy
Pregnancy
Health

Keywords

  • Adjuvant
  • Breast cancer
  • ESMO
  • Guidelines
  • Metastatic
  • NCCN

ASJC Scopus subject areas

  • Surgery

Cite this

Zagouri, F., Liakou, P., Bartsch, R., Peccatori, F. A., Tsigginou, A., Dimitrakakis, C., ... Azim, H. A. (2015). Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal. Breast, 24(4), 513-523. https://doi.org/10.1016/j.breast.2015.02.031

Discrepancies between ESMO and NCCN breast cancer guidelines : An appraisal. / Zagouri, Flora; Liakou, Paraskevi; Bartsch, Rupert; Peccatori, Fedro A.; Tsigginou, Alexandra; Dimitrakakis, Constantine; Zografos, George C.; Dimopoulos, Meletios Athanassios; Azim, H. A.

In: Breast, Vol. 24, No. 4, 01.08.2015, p. 513-523.

Research output: Contribution to journalArticle

Zagouri, F, Liakou, P, Bartsch, R, Peccatori, FA, Tsigginou, A, Dimitrakakis, C, Zografos, GC, Dimopoulos, MA & Azim, HA 2015, 'Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal', Breast, vol. 24, no. 4, pp. 513-523. https://doi.org/10.1016/j.breast.2015.02.031
Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C et al. Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal. Breast. 2015 Aug 1;24(4):513-523. https://doi.org/10.1016/j.breast.2015.02.031
Zagouri, Flora ; Liakou, Paraskevi ; Bartsch, Rupert ; Peccatori, Fedro A. ; Tsigginou, Alexandra ; Dimitrakakis, Constantine ; Zografos, George C. ; Dimopoulos, Meletios Athanassios ; Azim, H. A. / Discrepancies between ESMO and NCCN breast cancer guidelines : An appraisal. In: Breast. 2015 ; Vol. 24, No. 4. pp. 513-523.
@article{4359597e4ae94f4cb7dd74b2c9f5fbe3,
title = "Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal",
abstract = "An ever growing number of medical organizations, societies, working groups and governmental agencies issue algorithms i.e. guidelines, of decision making flowcharts in diagnosis and treatment in a variety of diseases. In the field of evidence-based diagnosis and treatment of breast cancer, a large number of guidelines are available both from medical associations and national health departments. Among the most appreciated and utilized comprehensive guides is the European Society for Medical Oncology (ESMO) Breast Cancer Guidelines and from the other side of the Atlantic the National Comprehensive Cancer Network (NCCN) Guidelines in Breast Cancer. Although there is much concordance between the guidelines from these two organizations, it is intriguing to locate their discrepancies also. The aim of this report is to present a number of different points between ESMO and NCCN in the whole spectrum of breast cancer management, from prevention and diagnosis to treatment and follow up. This systematic review was performed in accordance with the PRISMA guidelines using a predefined search strategy and summarizes in detail, the differences between ESMO and NCCN guidelines regarding genetic risk evaluation and screening, surgery, chemotherapy, endocrine treatment, targeted biological agents, radiotherapy, pregnancy and fertility and follow-up.",
keywords = "Adjuvant, Breast cancer, ESMO, Guidelines, Metastatic, NCCN",
author = "Flora Zagouri and Paraskevi Liakou and Rupert Bartsch and Peccatori, {Fedro A.} and Alexandra Tsigginou and Constantine Dimitrakakis and Zografos, {George C.} and Dimopoulos, {Meletios Athanassios} and Azim, {H. A.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.breast.2015.02.031",
language = "English",
volume = "24",
pages = "513--523",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Discrepancies between ESMO and NCCN breast cancer guidelines

T2 - An appraisal

AU - Zagouri, Flora

AU - Liakou, Paraskevi

AU - Bartsch, Rupert

AU - Peccatori, Fedro A.

AU - Tsigginou, Alexandra

AU - Dimitrakakis, Constantine

AU - Zografos, George C.

AU - Dimopoulos, Meletios Athanassios

AU - Azim, H. A.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - An ever growing number of medical organizations, societies, working groups and governmental agencies issue algorithms i.e. guidelines, of decision making flowcharts in diagnosis and treatment in a variety of diseases. In the field of evidence-based diagnosis and treatment of breast cancer, a large number of guidelines are available both from medical associations and national health departments. Among the most appreciated and utilized comprehensive guides is the European Society for Medical Oncology (ESMO) Breast Cancer Guidelines and from the other side of the Atlantic the National Comprehensive Cancer Network (NCCN) Guidelines in Breast Cancer. Although there is much concordance between the guidelines from these two organizations, it is intriguing to locate their discrepancies also. The aim of this report is to present a number of different points between ESMO and NCCN in the whole spectrum of breast cancer management, from prevention and diagnosis to treatment and follow up. This systematic review was performed in accordance with the PRISMA guidelines using a predefined search strategy and summarizes in detail, the differences between ESMO and NCCN guidelines regarding genetic risk evaluation and screening, surgery, chemotherapy, endocrine treatment, targeted biological agents, radiotherapy, pregnancy and fertility and follow-up.

AB - An ever growing number of medical organizations, societies, working groups and governmental agencies issue algorithms i.e. guidelines, of decision making flowcharts in diagnosis and treatment in a variety of diseases. In the field of evidence-based diagnosis and treatment of breast cancer, a large number of guidelines are available both from medical associations and national health departments. Among the most appreciated and utilized comprehensive guides is the European Society for Medical Oncology (ESMO) Breast Cancer Guidelines and from the other side of the Atlantic the National Comprehensive Cancer Network (NCCN) Guidelines in Breast Cancer. Although there is much concordance between the guidelines from these two organizations, it is intriguing to locate their discrepancies also. The aim of this report is to present a number of different points between ESMO and NCCN in the whole spectrum of breast cancer management, from prevention and diagnosis to treatment and follow up. This systematic review was performed in accordance with the PRISMA guidelines using a predefined search strategy and summarizes in detail, the differences between ESMO and NCCN guidelines regarding genetic risk evaluation and screening, surgery, chemotherapy, endocrine treatment, targeted biological agents, radiotherapy, pregnancy and fertility and follow-up.

KW - Adjuvant

KW - Breast cancer

KW - ESMO

KW - Guidelines

KW - Metastatic

KW - NCCN

UR - http://www.scopus.com/inward/record.url?scp=84930767181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930767181&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2015.02.031

DO - 10.1016/j.breast.2015.02.031

M3 - Article

C2 - 25818651

AN - SCOPUS:84930767181

VL - 24

SP - 513

EP - 523

JO - Breast

JF - Breast

SN - 0960-9776

IS - 4

ER -